Literature DB >> 24267274

Two birds with one stone: dual p110δ and p110γ inhibition.

Klaus Okkenhaug1.   

Abstract

In this issue of Chemistry & Biology, Winkler and colleagues describe the discovery and preclinical development of IPI-145, a new inhibitor of the phosphoinositide 3-kinase (PI3K) isoforms p110δ and p110γ that have entered clinical trials.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24267274      PMCID： PMC4523579          DOI： 10.1016/j.chembiol.2013.11.002

Source DB:  PubMed          Journal:  Chem Biol        ISSN： 1074-5521


  10 in total

1.  Targeting nonclassical oncogenes for therapy in T-ALL.

Authors:  Prem S Subramaniam; Dosh W Whye; Evgeni Efimenko; Jianchung Chen; Valeria Tosello; Kim De Keersmaecker; Adam Kashishian; Mary Ann Thompson; Mireia Castillo; Carlos Cordon-Cardo; Utpal P Davé; Adolfo Ferrando; Brian J Lannutti; Thomas G Diacovo
Journal:  Cancer Cell       Date:  2012-04-17       Impact factor: 31.743

2.  Role of the phosphoinositide 3-kinase p110delta in generation of type 2 cytokine responses and allergic airway inflammation.

Authors:  Baher F Nashed; Tingting Zhang; Monther Al-Alwan; Ganesh Srinivasan; Andrew J Halayko; Klaus Okkenhaug; Bart Vanhaesebroeck; Kent T Hayglass; Aaron J Marshall
Journal:  Eur J Immunol       Date:  2007-02       Impact factor: 5.532

3.  Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase gamma-deficient mice.

Authors:  Masahide Takeda; Wataru Ito; Masako Tanabe; Shigeharu Ueki; Hikari Kato; Junko Kihara; Tomomi Tanigai; Takahito Chiba; Kazutoshi Yamaguchi; Hiroyuki Kayaba; Yumiko Imai; Kaori Okuyama; Isao Ohno; Takehiko Sasaki; Junichi Chihara
Journal:  J Allergy Clin Immunol       Date:  2009-02-20       Impact factor: 10.793

Review 4.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

5.  Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils.

Authors:  Tara M Randis; Kamal D Puri; Hairu Zhou; Thomas G Diacovo
Journal:  Eur J Immunol       Date:  2008-05       Impact factor: 5.532

6.  Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs.

Authors:  Olusegun Williams; Benjamin T Houseman; Eric J Kunkel; Brian Aizenstein; Randy Hoffman; Zachary A Knight; Kevan M Shokat
Journal:  Chem Biol       Date:  2010-02-26

7.  PI3Kβ plays a critical role in neutrophil activation by immune complexes.

Authors:  Suhasini Kulkarni; Cassian Sitaru; Zoltan Jakus; Karen E Anderson; George Damoulakis; Keith Davidson; Misa Hirose; Jatinder Juss; David Oxley; Tamara A M Chessa; Faruk Ramadani; Herve Guillou; Anne Segonds-Pichon; Anja Fritsch; Gavin E Jarvis; Klaus Okkenhaug; Ralf Ludwig; Detlef Zillikens; Attila Mocsai; Bart Vanhaesebroeck; Len R Stephens; Phillip T Hawkins
Journal:  Sci Signal       Date:  2011-04-12       Impact factor: 8.192

8.  The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases.

Authors:  Edward Banham-Hall; Menna R Clatworthy; Klaus Okkenhaug
Journal:  Open Rheumatol J       Date:  2012-09-07

Review 9.  Signaling by the phosphoinositide 3-kinase family in immune cells.

Authors:  Klaus Okkenhaug
Journal:  Annu Rev Immunol       Date:  2013-01-16       Impact factor: 28.527

10.  Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation.

Authors:  Hong Ji; Felix Rintelen; Caroline Waltzinger; Dominique Bertschy Meier; Antonio Bilancio; Wayne Pearce; Emilio Hirsch; Matthias P Wymann; Thomas Rückle; Montserrat Camps; Bart Vanhaesebroeck; Klaus Okkenhaug; Christian Rommel
Journal:  Blood       Date:  2007-07-12       Impact factor: 22.113
  10 in total
  6 in total

1.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Authors:  K Balakrishnan; M Peluso; M Fu; N Y Rosin; J A Burger; W G Wierda; M J Keating; K Faia; S O'Brien; J L Kutok; V Gandhi
Journal:  Leukemia       Date:  2015-04-28       Impact factor: 11.528

2.  Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.

Authors:  Jun-Ichi Kawada; Shotaro Ando; Yuka Torii; Takahiro Watanabe; Yoshitaka Sato; Yoshinori Ito; Hiroshi Kimura
Journal:  Cancer Med       Date:  2018-03-09       Impact factor: 4.452

Review 3.  Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?

Authors:  Ebru Aydin; Sebastian Faehling; Mariam Saleh; Laura Llaó Cid; Martina Seiffert; Philipp M Roessner
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

Review 4.  Dual Kinase Targeting in Leukemia.

Authors:  Luca Mologni; Giovanni Marzaro; Sara Redaelli; Alfonso Zambon
Journal:  Cancers (Basel)       Date:  2021-01-01       Impact factor: 6.639

Review 5.  Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and -γ.

Authors:  Sanjay Chandrasekaran; Christopher Ronald Funk; Troy Kleber; Chrystal M Paulos; Mala Shanmugam; Edmund K Waller
Journal:  Front Immunol       Date:  2021-08-26       Impact factor: 7.561

Review 6.  PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives.

Authors:  Iwona Hus; Bartosz Puła; Tadeusz Robak
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.